Bora Kunay

Bora Kunay

Auto-generated profile, based on publicly available information

Bora Kunay

Division of Gastroenterology, Hepatology and Nutrition Disease, Department of Pediatrics, Medical School of Ege University, İzmir, Türkiye

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 June 2024 in Journal of Medical Virology
Verified
Journal Article
Open access
DBdoğan barut
doğan barut
SASema Yildirim Arslan
Sema Yildirim Arslan
KBKunay Bora
Kunay Bora
VUVEYSEL UMMAN
VEYSEL UMMAN
DBDernek Benan
Dernek Benan
ASAydogdu Sema
Aydogdu Sema
The most prevalent malignancy that complicates both adult and pediatric solid organ transplantation is post‐transplant lymphoproliferative disorder (PTLD). This study aimed to analyze the clinical and pathological characteristics, treatments, and outcomes of Epstein‐Barr virus (EBV) DNAemia and PTLD in pediatric liver transplant recipients. A retrospective chart review was performed on 112 patients less than 18 years of age who underwent isolated orthotopic liver transplantation (OLT) between 2010 and 2022 at Ege University Children's Hospital. Data gathered for 1‐year post‐OLT included age at OLT, EBV, immunoglobulin (Ig)M/IgG status of the donor and recipient, indication for OLT, induction regimen, all immunosuppression levels, date and result of EBV polymerase chain reaction testing, rejection episodes documented by liver biopsy, and the development of PTLD. Forty‐nine patients (43.75%) developed EBV DNAemia (median interval from surgery: 2 months, min–max: 2–36), of which 43 (87.8%) grafts came from living donors, and 6 (12.2%) came from deceased donors. Nine (18.4%) patients died during follow‐up, and eight (16.3%) developed PTLD. Of these 8 patients; five patients developed EBV‐related disease, one child developed hemophagocytic lymphohistiocytosis, one developed aplastic anemia, and one child developed B cell lymphoma. When PTLD patients and without‐PTLD patients were compared, pediatric intensive care unit hospitalization, abnormal bone marrow biopsy findings, lymphadenopathy, age at diagnosis of EBV DNAemia, EBV viral load, tacrolimus (FK 506) pre‐infection, were higher and tacrolimus 1‐month levels were lower in patients with PTLD ( p < 0.05). In logistic regression analysis, we showed that the age at diagnosis of EBV DNAemia was significantly higher in children with PTLD ( p = 0.045; OR: 1.389; 95% CI: 1.007–1.914). PTLD is a rare but severe complication associated with EBV after OLT. This study demonstrated that PTLD is associated with older age, higher tacrolimus blood levels before EBV DNAemia, and higher peak EBV viral load at 1 month of EBV DNAemia.

7 October 2024 in The Turkish Journal of Pediatrics
Verified
Journal Article
Open access
PDF file
DBdoğan barut
doğan barut
BKBora Kunay
Bora Kunay
SASema Yildirim Arslan
Sema Yildirim Arslan
GAGözde Kayalı Akkuş
Gözde Kayalı Akkuş
ZBZumrut Sahbudak Bal
Zumrut Sahbudak Bal
SASema Aydoğdu
Sema Aydoğdu
Background. Cryptococcus neoformans causes cryptococcosis, primarily affecting immunocompromised individuals, including solid-organ transplant recipients, and, less frequently, immunocompetent people. Case. A 15-year-old male with congenital hepatic fibrosis, portal hypertension, and cirrhosis underwent orthotopic liver transplantation. He received perioperative antimicrobial and antifungal prophylaxis and continued immunosuppressive treatment. Thirty months post-transplant, he presented with fever, hypertension, and sacroiliac joint pain. Peripheral blood cultures showed C. neoformans, confirmed by pan-fungal polymerase chain reaction assay and latex agglutination tests. Despite initial treatment with intravenous (IV) fluconazole, his condition worsened, necessitating intubation for acute hypoxic respiratory failure. Magnetic resonance imaging and computed tomography scans indicated disseminated cryptococcosis with lymphadenitis, possible meningitis, and pneumonia. Treatment was escalated to IV liposomal amphotericin B and 5-flucytosine, while reducing immunosuppressive treatment. Despite negative fungal cultures on the tenth day, the patient deteriorated, developing pancreatitis, pneumonia, and massive gastrointestinal bleeding, leading to death on the 35th day of hospitalization. Conclusion. This case shows the severity and complexity of managing disseminated cryptococcosis in pediatric liver transplant recipients. Aggressive therapy and early identification are essential for improving outcomes in these high-risk patients.

5 October 2024 in Clinical Transplantation
Verified
Journal Article
Open access
DBdoğan barut
doğan barut
BKBora Kunay
Bora Kunay
VUVEYSEL UMMAN
VEYSEL UMMAN
ETEzgi Kıran Taşcı
Ezgi Kıran Taşcı
ZKZiya Kumcuoğlu
Ziya Kumcuoğlu
SASema Aydogdu
Sema Aydogdu
Objectives: The influence of advancing fibrosis on graft survival in the context of pediatric liver transplantation accentuates the critical role of protocol‐driven liver biopsies, a practice adopted by numerous medical centers. Consequently, the exigency for noninvasive methodologies to assess graft fibrosis assumes heightened importance when conventional clinical and laboratory parameters fail to reveal signs of liver damage.Methods: This study aimed to assess the reliability of transient elastography (TE) in pediatric liver transplant recipients to detect graft fibrosis and compare the results of TE in patients who underwent biopsy.Results: This prospective cohort study included liver transplanted children who underwent biopsy at Ege University Children's Hospital between October 1, 2021, and October 31, 2022, and a healthy control group. According to TE, fibrosis was detected in 40 patients, and no fibrosis was detected in 50. The median time to develop fibrosis was 100 months (95% CI [83.1–116.8]). A statistically significant positive correlation existed between LSM and METAVIR fibrosis score (r = 0.562, p = 0.001). There was a statistically significant difference in LSM between patients with F2 fibrosis (7.8–8.8 kPa ± 3.2) compared to patients with F0 fibrosis (5.2 kPa ± 0.7) (p = 0.005) and F1 fibrosis (6.1 kPa ± 1.5) (p = 0.041), on ANOVA.Conclusion: Liver allograft fibrosis is common in long‐term follow‐up in children who have undergone liver transplantation. Abnormal TE may guide physicians to consider liver biopsy to detect late allograft fibrosis in these children.

11 February 2025 in The Turkish Journal of Pediatrics
Verified
Journal Article
Open access
PDF file
DBdoğan barut
doğan barut
BKBora Kunay
Bora Kunay
SASema Yildirim Arslan
Sema Yildirim Arslan
AUAyça Aydın Uysal
Ayça Aydın Uysal
ZBZumrut Sahbudak Bal
Zumrut Sahbudak Bal
SASema Aydoğdu
Sema Aydoğdu

7 November 2025 in Turkish Journal of Gastroenterology
Verified
Journal Article
Open access
DBdoğan barut
doğan barut
KBKunay Bora
Kunay Bora
SASema Yildirim Arslan
Sema Yildirim Arslan
VUVEYSEL UMMAN
VEYSEL UMMAN
DBDernek Benan
Dernek Benan
MKMiray Karakoyun
Miray Karakoyun
Background/Aims: Cytomegalovirus (CMV) infection is a significant complication in pediatric liver transplant recipients. This study aimed to assess the incidence, risk factors, and suspected effects of CMV infection in children undergoing liver transplantation and compared acyclovir and ganciclovir-based preventive therapy. Materials and Methods: The study included 92 patients who had liver transplants at Ege University Transplantation Unit between 2011 and 2021. Sixty-four pediatric patients with preoperative CMV immunoglobulin G (IgG) positivity were analyzed. Patients with early mortality, re-transplantation within 6 months, and CMV IgG negativity were excluded. Results: The study consisted of 39 females (61%) and 25 males (39%), with a median age of 5.3 years at transplantation. Cytomegalovirus viremia occurred in 42 patients (65%), and CMV disease developed in 7 patients (10%). The median duration of CMV viremia was 40 days, and CMV disease was 105 days. Age was significantly associated with CMV disease development, with younger patients at higher risk (P = .007). The choice of antiviral treatment (acyclovir vs. valganciclovir) did not significantly impact the development of CMV vire mia or disease. Conclusion: Cytomegalovirus viremia and disease are common in pediatric liver transplant recipients, with younger age being a signifi cant risk factor for CMV disease. However, CMV viremia and disease did not significantly impact this cohort’s graft loss, acute cellular rejection, or mortality. The choice of antiviral treatment and immunosuppression protocols did not influence CMV outcomes. These find ings highlight the need for vigilant monitoring and tailored management strategies for CMV in pediatric liver transplantation. Cite this article as: Dogan B, Bora K, Sema YA, et al. CMV infection in pediatric liver transplantation and comparison of prophylaxis methods depending on donor serostatus. Turk J Gastroenterol. Published online November 7, 2025. doi:10.5152/tjg.2025.24585.

3 June 2021 in Medical Bulletin of Haseki
Verified
Journal Article
Closed access
ÖYözge Yılmaz
özge Yılmaz
AYADEM YASAR
ADEM YASAR
YSYurda Simsek
Yurda Simsek
SASedef Alpdogan
Sedef Alpdogan
BKBora Kunay
Bora Kunay
HYHasan Yuksel
Hasan Yuksel